Izervay: adverse event reports filed with FDA

254

reports as suspect product

0% of all reports · about 92 a year

110

reports, 12 months to June 2026

107 in the 12 months before

44.1%

marked serious by the reporter

58.7% across the class

2%

record death among outcomes, as reported

5 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Izervay reports recording the termmedian drug in complement inhibitor

1. Off label useused for a purpose or in a way not on the label8.7%22
2. Visual impairmentreduced vision8.7%22
3. Eye paineye pain7.9%20
4. Vision blurredblurred vision6.7%17
5. Endophthalmitisinfection inside the eye5.9%15
6. Choroidal neovascularisation5.5%14
7. Intercepted product preparation error5.5%14
8. Intraocular pressure increasedraised pressure in the eye5.1%13
9. Product temperature excursion issue5.1%13
10. Eye inflammation4.3%11
11. Inappropriate schedule of product administrationthe product was taken at the wrong times3.9%10
12. Product storage errorthe product was stored wrongly3.9%10
13. No adverse eventno adverse event was reported3.5%9
14. Product packaging quantity issue3.5%9
15. Vitritis3.5%9
16. Needle issuea problem with the needle3.1%8
17. Uveitis3.1%8
18. Visual acuity reducedreduced sharpness of vision3.1%8
19. Condition aggravatedthe condition being treated got worse2.8%7
20. Iritis2.8%7
21. Ocular hyperaemiaa red eye2.8%7
22. Product contaminationcontamination of the product2.8%7
23. Product packaging issuea problem with the packaging2.8%7
24. Vitreous floatersfloaters in vision2.8%7
25. Blindness transient2.4%6
26. Intercepted product storage error2.4%6
27. Corneal oedema2%5
28. Inadequate aseptic technique in use of product2%5
29. Non-infectious endophthalmitis2%5
30. Deaththe patient died; cause not stated by this term1.6%4

Top 30 of 63 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 6 drugs in the complement inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 69,459 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 100% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 254 reports.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the complement inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Izervay as a suspect or interacting product; reports listing it only as a concomitant medication (18) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.